WhaleCreep

Avidity Partners Management LP 13F holdings, Q1 2025

Hedge fundSEC filingsCompare with another fundHoldings as of 2025-03-31, filed 2025-05-15

Avidity Partners Management LP disclosed 63 US equity positions worth $484.9m in its Q1 2025 13F filing. Its largest position is BSX at 7.0% of the reported book, followed by DNTH and UNH. Versus Q4 2024 it opened 19 new positions, added to 3, reduced 37 and exited 17.

$485m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
63
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
7.0%
Largest position
The largest single position as a share of the reported equity book.
43.8%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
34
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2024: 19 new, 3 added, 37 reduced, 17 exited

50 of 63
BSX BOSTON SCIENTIFIC CORPHealthcare7.0%$33.9m336,000−35%reduced
DNTH DIANTHUS THERAPEUTICS INCHealthcare6.4%$31.2m1.72m−40%reduced
UNH UNITEDHEALTH GROUP INCHealthcare5.5%$26.4m50,500−16%reduced
CGON CG ONCOLOGY INCHealthcare5.0%$24.0m980,942−11%reduced
HUM HUMANA INCHealthcare4.4%$21.4m81,000−9.2%reduced
NTRA NATERA INCHealthcare3.5%$16.9m119,200−47%reduced
REGN REGENERON PHARMACEUTICALSHealthcare3.3%$16.1m25,400+202%added
EXK EXACT SCIENCES CORPBasic Materials3.2%$15.3m353,000−41%reduced
BEAM BEAM THERAPEUTICS INCHealthcare2.9%$13.9m709,517–new
GKOS GLAUKOS CORPHealthcare2.7%$13.2m134,000−21%reduced
DXCM DEXCOM INCHealthcare2.5%$12.3m180,000−43%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare2.4%$11.7m322,100−8.5%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.3%$11.4m925,000−38%reduced
COR CENCORA INCHealthcare2.3%$10.9m39,300–new
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.0%$9.9m80,000−66%reduced
THC TENET HEALTHCARE CORPHealthcare2.0%$9.7m72,000−47%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.0%$9.5m85,700−61%reduced
DHR DANAHER CORP DELHealthcare1.9%$9.1m44,500−34%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare1.9%$9.0m77,000−59%reduced
INSM INSMED INCHealthcare1.7%$8.2m107,000−54%reduced
OGN ORGANON & COHealthcare1.6%$8.0m535,000–new
TMO THERMO FISHER SCIENTIFIC INCHealthcare1.6%$7.7m15,500−65%reduced
XENE XENON PHARMACEUTICALS INCHealthcare1.6%$7.7m229,000−52%reduced
XBI SPDR SERIES TRUST–1.6%$7.6m94,000–new
CNTA CENTESSA PHARMACEUTICALS PLC–1.6%$7.6m529,000−55%reduced
RVMD REVOLUTION MEDICINES INCHealthcare1.6%$7.5m213,000−52%reduced
TEVA TEVA PHARMACEUTICAL INDS LTDHealthcare1.5%$7.4m481,000–new
AVTR AVANTOR INCHealthcare1.5%$7.3m453,000−52%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare1.5%$7.3m445,000−61%reduced
DOCS DOXIMITY INCHealthcare1.5%$7.1m122,500–new
JANX JANUX THERAPEUTICS INCHealthcare1.4%$7.0m258,000−65%reduced
HQY HEALTHEQUITY INCHealthcare1.4%$6.9m78,000–new
2655787D BLUEPRINT MEDICINES CORP–1.3%$6.1m68,500−61%reduced
UTHR UNITED THERAPEUTICS CORP DELHealthcare1.1%$5.2m16,800–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.0%$5.0m800,000−42%reduced
IMUX IMMUNIC INCHealthcare1.0%$4.9m4.45m−44%reduced
BRKR BRUKER CORPHealthcare1.0%$4.8m115,000+51%added
CATX PERSPECTIVE THERAPEUTICS INC–1.0%$4.7m2.20m−18%reduced
CNTX CONTEXT THERAPEUTICS INC–0.9%$4.6m7.48m0.0%held
ORKA ORUKA THERAPEUTICS INCHealthcare0.7%$3.6m352,1240.0%held
UNIQURE NV no ticker–0.7%$3.6m336,200+51%added
BHVN BIOHAVEN LTDHealthcare0.7%$3.5m145,000−35%reduced
ARVN ARVINAS INCHealthcare0.6%$2.9m413,162−70%reduced
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.6%$2.8m169,000–new
RPRX ROYALTY PHARMA PLCHealthcare0.6%$2.7m87,000–new
BBIO BRIDGEBIO PHARMA INCHealthcare0.5%$2.6m75,000–new
2KZ0 KEZAR LIFE SCIENCES INC–0.5%$2.5m502,6000.0%held
AKROEUR AKERO THERAPEUTICS INC–0.5%$2.3m57,000−30%reduced
SLNOEUR SOLENO THERAPEUTICS INC–0.5%$2.3m32,000–new
CAPR CAPRICOR THERAPEUTICS INCHealthcare0.5%$2.3m239,000–new

Exited since Q4 2024

17 rows
ISRG INTUITIVE SURGICAL INC3.4%$33.8m
ACHC ACADIA HEALTHCARE COMPANY IN2.6%$26.1m
KYMR KYMERA THERAPEUTICS INC2.0%$20.1m
ILMN ILLUMINA INC1.5%$14.7m
ABBV ABBVIE INC1.4%$14.3m
RCKT ROCKET PHARMACEUTICALS INC1.3%$13.2m
BMY BRISTOL-MYERS SQUIBB CO1.2%$12.2m
TMDX TRANSMEDICS GROUP INC1.2%$12.0m
SGRY SURGERY PARTNERS INC1.1%$10.9m
ORIC ORIC PHARMACEUTICALS INC1.0%$10.2m
INCY INCYTE CORP0.9%$9.0m
ASND ASCENDIS PHARMA A/S0.9%$8.5m
ITCIEUR INTRA-CELLULAR THERAPIES INC0.8%$8.1m
KROS KEROS THERAPEUTICS INC0.3%$3.3m
DYN DYNE THERAPEUTICS INC0.2%$2.3m
COGT COGENT BIOSCIENCES INC0.2%$2.2m
BLUEBIRD BIO INC no ticker0.07%$680k

Sector mix

  • Healthcare87.7%
  • Unclassified9.2%
  • Basic Materials3.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters